仙琚制药(002332.SZ)：醋酸地塞米松片新增规格通过一致性评价

Core Viewpoint - Xianju Pharmaceutical (002332.SZ) has received approval from the National Medical Products Administration for a supplemental application regarding Acetate Dexamethasone Tablets, which has passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1: Product Approval - The company has obtained a notification for the approval of Acetate Dexamethasone Tablets, indicating regulatory compliance and potential market expansion [1] - The new specification of Acetate Dexamethasone Tablets enhances the product portfolio of the company [1] Group 2: Product Indications - Acetate Dexamethasone Tablets are classified as corticosteroids and are primarily used for allergic and autoimmune inflammatory diseases [1] - Indications include connective tissue diseases, severe bronchial asthma, dermatitis, ulcerative colitis, acute leukemia, and malignant lymphoma [1]